IRIX (IRIDEX) Risk Assessment


IRIX IRIDEX Corp IRIX
62 GF Score
Price $1.13
GF Value $1.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is IRIDEX Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of IRIDEX is: High Risk: High uncertainty.

IRIDEX  (NAS:IRIX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

IRIDEX Risk Assessment Related Terms

IRIX vs ICCM, LFWD, GTHP: Risk Assessment Comparison

For the Medical Devices subindustry, IRIDEX's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRIDEX Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Risk Assessment distribution charts can be found below:

* The bar in red indicates where IRIDEX's Risk Assessment falls into.


IRIX
62GF Score
IRIDEX Corp IRIX
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IRIDEX (IRIX) Overvalued in 2026?

Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued. The current stock price of $1.13 is trading 33.5% below its estimated GF Value™ of $1.70. GuruFocus considers IRIDEX to be Possible Value Trap.

Key valuation signals for IRIX:

  • Risk Assessment:
  • GF Value™: $1.70 vs. price of $1.13 (33.5% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRIDEX Business Description

Address 1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
62GF Score

Get the complete analysis for IRIX

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.13
Price
$1.70
GF Value